Skip to main content
. 2021 Aug 2;5(15):2958–2964. doi: 10.1182/bloodadvances.2021004295

Figure 3.

Figure 3.

Overall survival of patients treated with rituximab originator or rituximab biosimilars. Kaplan-Meier curves depicting 3-year overall survival in patients with DLBCL treated with rituximab originator (R-originator, in red) or rituximab biosimilars (R-biosimilars, in blue) combined with standard CHOP chemotherapy regimens. The 95% confidence intervals are depicted as blue/red shaded areas.